Marksans Pharma Ltd

Stage 2 · Advancing · week 20Setup 6.6 ★★ GoodStrong +7.3

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the Uni… More about the company

₹325.5
+0.32% today
₹14,748 Cr · Mid cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dPharmaceuticals 53.8%+3.8 pts
Loading price chart…
vs 52W High
-6.4%
₹156.9 lo₹347.6 hi
6.4% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 20
1w13w26w
Week 20 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
41.5%
200 DMA: ₹230 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.58x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +0.8% vs MA50 +9.0%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-0.4%
3M
+23.5%
6M
+95.7%
YTD
+78.0%
1Y
+95.7%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
This stock ranks #9 of 77 Stage 2 stocks in Health Care by RS. Leading the sector.
Industry
Pharmaceuticals
↑ Building
Stage 2%
53.8%
20d Δ
+3.8pp
1M return
-0.9%
3M return
+3.6%
Industry Stage-2 % · last 20 days
Ranks #9 of 61 Stage 2 stocks in this industry. Top tier.
Stage Cycle Timeline2023-07-12 → 2026-10-07
S2 14w
S2 16w
S2 39w
S4 15w
S4 14w
S2 20w
2023-07-122026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 14w → S3 4w → S2 16w → S3 7w → S2 39w → S3 7w → S4 11w → S1 11w → S4 15w → S1 8w → S4 14w → S1 4w → S2 20w current
Total tracked: 168 weeks across 13 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-07
Pullback Hunter
Latest: 2026-08-21
60 appearances in last 60 days. First seen: 2026-07-13.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S2
Wk 20 · Vol 0.58x
2026-10-06S2
Wk 20 · Vol 0.85x
2026-10-05S2
Wk 20 · Vol 0.43x
2026-10-01S2
Wk 19 · Vol 0.66x
2026-09-30S2
Wk 19 · Vol 0.88x
2026-09-29S2
Wk 19 · Vol 1.27x
2026-09-28S2
Wk 19 · Vol 0.52x
2026-09-25S2
Wk 19 · Vol 0.40x
2026-09-24S2
Wk 18 · Vol 0.80x
2026-09-23S2
Wk 18 · Vol 0.94x
2026-09-22S2
Wk 18 · Vol 0.44x
2026-09-21S2
Wk 18 · Vol 0.85x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
Moving averages & range
50 DMA
₹313.9
200 DMA
₹230
52W High
₹347.6
52W Low
₹156.9
5D Low
₹322.3
Resistance levels (recent highs)
20d High
₹347.6
60d High
₹347.6
120d High
₹347.6
250d High
₹347.6
Next resistance
+6.8%
to 20d High
Ask the Market AI about MARKSANSAsk →
P/E (TTM)
27.0
Forward 19.3
Earnings Growth (YoY)
+8.2%
Revenue +10.6%
Dividend Yield
0.36%
P/B 4.2
About this companyHealth Care· Pharmaceuticals

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.